Digital Deals And Life Sciences: Avoiding Death By A Thousand Pilots
EY executive survey yields insights into how digital technology is helping drive biopharma deal strategy and aiding companies to meet competitive challenges.
You may also be interested in...
Duo aims to get Pear's THRIVE digital therapeutic approved, and to develop a new application to treat MS patients, then seek validation in clinical studies.
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.
The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.